Granulocyte–macrophage colony‐stimulating factor (GM‐CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti‐GM‐CSF monoclonal antibody

BACKGROUND: The relevance of granulocyte–macrophage colony‐stimulating factor (GM‐CSF) in the management of psoriasis has not been studied previously. GM‐CSF is important in the initiation and maintenance of chronic inflammatory processes. OBJECTIVES: To investigate the clinical use of GM‐CSF neutra...

Descripción completa

Detalles Bibliográficos
Autores principales: Papp, K.A., Gooderham, M., Jenkins, R., Vender, R., Szepietowski, J.C., Wagner, T., Hunt, B., Souberbielle, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379964/
https://www.ncbi.nlm.nih.gov/pubmed/30207587
http://dx.doi.org/10.1111/bjd.17195

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7379964/
https://www.ncbi.nlm.nih.gov/pubmed/30207587
http://dx.doi.org/10.1111/bjd.17195

Ejemplares similares